Dr. Reddy’s to acquire select Anti-Allergy brands from Glenmark in Russia, Ukraine, Kazakhstan and Uzbekistan Kumar Jeetendra | November 29, 2020 Hyderabad, India. November 28, 2020 — Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced that it has entered into a definitive agreement with Glenmark Pharmaceuticals Ltd. to acquire, subject to completion of certain precedent actions and closing activities, brands Momat Rino …
AMZELL to initiate FDA-approved Phase 3 trial of innovative injectable treatment for infantile epileptic disease Kumar Jeetendra | November 26, 2020 Specialist development pharmaceutical company AMZELL B.V has concluded discussions with the FDA ahead of initiating a Phase 3 trial of its new treatment for infantile epileptic disease, AMZ002. The Phase 3 trial will compare AMZ002 to another active treatment in a superiority study, as a placebo-controlled trial would not be ethical for this patient population. …
Covaxin’s stage 3 preliminaries to begin in Sir JJ Hospital in Mumbai Kumar Jeetendra | November 26, 2020 The phase-3 clinical trials of India’s own COVID-19 vaccine candidate — Covaxin – will begin at Sir JJ Hospital in Mumbai. The medical facility is reportedly the second one in Maharashtra’s capital to start human trials of this vaccine candidate against the novel coronavirus following BMC-run Sion hospital. Covaxin has been developed by the Hyderabad-based …
Dexamethasone use could reduce immune checkpoint inhibitor viability in glioblastoma patients Kumar Jeetendra | November 25, 2020 Bottom Line: One of patients with glioblastoma getting an immune checkpoint inhibitor, people who obtained the corticosteroid dexamethasone at baseline for cerebral edema had significantly worse overall survival. Journal Where the Study was Released: Clinical Cancer Research, a journal of the American Association for Cancer Research Author: David A. Reardon, MD, clinical director of the …
BioNTech, Fosun start Phase II preliminary of COVID-19 vaccine in China Kumar Jeetendra | November 25, 2020 BioNTech and Shanghai Fosun Pharmaceutical said on Wednesday they would launch a Phase II clinical trial of BioNTech’s experimental COVID-19 vaccine in China. The vaccine, known as BNT162b2, will be tested on volunteers at the Jiangsu Provincial Center for Disease Control and Prevention to assess safety and immunogenicity, eyeing future acceptance in China, both firms …
Strides Pharma Science gets USFDA gesture for Prednisone tablets Kumar Jeetendra | November 24, 2020 New Delhi, Nov 23 (PTI) Strides Pharma Science Ltd on Monday said it has received approval from the US health regulator for its generic version of Prednisone pills, prescribed for an assortment of conditions, including allergies, respiratory disease and arthritis. The approval for Prednisone pills by the US Food & Drug Administration (USFDA) given to …
MMR Vaccine may protect against COVID-19, says study Kumar Jeetendra | November 23, 2020 The measles-mumps-rubella (MMR) vaccine may provide protection against COVID-19, according to a study that may also explain why kids have a much lower case rate and death rate of the disease than adults. The MMR vaccine has been theorised to provide protection against COVID-19, and the study, published in the journal mBio, provides further proof …
Study shows Favipiravir gives various advantages in COVID-19 treatment: Glenmark Pharmaceuticals Kumar Jeetendra | November 23, 2020 Drug firm Glenmark Pharmaceuticals on Monday said according to a recently released data the oral antifungal medication Favipiravir was found to provide multiple benefits in COVID-19 treatment including faster time to clinical cure. These findings have been observed in a randomised, controlled Phase 3 clinical study conducted by the organization and the results have been …
AstraZeneca will have 200 million COVID-19 antibody dosages by year-end Kumar Jeetendra | November 23, 2020 AstraZeneca will have enough of its own candidate vaccine for 200 million doses by the end of 2020, with drug substance for 700 million doses by the end of the first quarter of 2021 worldwide, operations executive Pam Cheng said on Monday. Cheng told a briefing that the company would keep the”active” drug substance in …
Unilever says its mouthwash will decrease 99.9% Covid in the wake of flushing Kumar Jeetendra | November 21, 2020 International FMCG major Unilever on November 21 said it will bring to India its mouthwash formulation, which, it claims, will reduce 99.9 percent of coronavirus after 30 minutes of rinsing. “Unilever has confirmed that preliminary lab test results reveal that mouthwash formulation containing CPC Technology reduces 99.9 percent of SARS-CoV-2, the virus which causes COVID-19, …
Asahi Kasei Pharma Contracts ProBioGen for the Advancement of their Biologics Pipeline Kumar Jeetendra | November 18, 2020 BERLIN, Germany, November 18, 2020 / B3C newswire / — ProBioGen AG announced the closing of a master service agreement with Asahi Kasei Pharma. As an expert CDMO in high-titer cell line development till large scale GMP manufacturing, ProBioGen will use its proprietary technologies, like the CHO.RiGHT® cell line development platform and DirectedLuck™ transposase technology, …
J&J expects information for US approval of COVID-19 antibody by February, says head researcher Kumar Jeetendra | November 18, 2020 Johnson & Johnson’s chief scientist said the drugmaker is recruiting over 1,000 people per day for the late-stage trial of its experimental COVID-19 vaccine and hopes to have all the data required to seek U.S. authorization by February or earlier. “From the end of the year or around the end of the year, we should …
